ponatinib,bevacizumab,nivolumab,atezolizumab,ipilimumab,cabozantinib,sunitinib
bms,roche,takeda,pfizer,incyte,otsuka
['atezo', 'cabo ', 'nivo', 'sunitinib', 'ipi/', 'rcc,(-irccs),(-srcc),(-urcc)', 'optic,(-optical),(-optics)', 'beva ']
analysis from immotion 151 (atezo/beva vs sunitinib in mrcc)--&gt;develop/valid of rna-seq signatures (188 genes): 1: angiogenic sig (tki+io) 2: immuneprolif (io/io) 3: neither
signatures used for optic ph2 trial to select mrcc pts for nivo/cabo or ipi/nivo #asco23 
MD, MSc | @UofTUrology @SUO_YUO Fellow & @IHPMEUofT CEHCR PhD| Previously: @MCG_Urology and @AUB_Lebanon 🇱🇧